We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Are GlaxoSmithKline plc & National Grid plc The Only Shares You Need To Own?

Roland Head asks whether National Grid plc (LON:NG) and GlaxoSmithKline plc (LON:GSK) have market-beating potential.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Is it possible to run a successful portfolio with just two shares? I wouldn’t recommend it, but if I decided to try, National Grid (LSE: NG) and GlaxoSmithKline (LSE: GSK) would probably be on my shortlist of stocks to consider.

Both companies appear to offer a combination of reliable long-term growth and generous dividend yields. Both firms are also very large. Together, National Grid and Glaxo account for 5.7% of the FTSE 100’s total market capitalisation. This makes them less likely than smaller companies to fail, although long periods of underperformance are still possible.

XXX

Not likely to underperform?

Indeed, many investors believe that GlaxoSmithKline has been underperforming over the last few years. Although the dividend has been maintained, the firm’s shares are currently trading 15% below their July 2013 high of 1,745p.

However, things now seem likely to change. Glaxo completed a major asset swap deal with Swiss firm Novartis last year. The firm’s sales rose by 4% and while profits were lower, a number of new products made a strong contribution for the first time.

I believe Glaxo’s restructuring has positioned it to deliver a sustained period of growth. Adjusted earnings per share are expected to rise to 85.3p this year, covering the firm’s forecast dividend of 81.9p per share for the first time in three years.

There’s also one more big change in the pipeline. The group’s chief executive, Sir Andrew Witty, is expected to leave next year. If GlaxoSmithKline shares continue to underperform the market, I suspect its next chief executive will come under pressured to break up the group.

Fund managers such as Neil Woodford hold the view that Glaxo would be worth more as two or three companies than it is as one. I suspect he’s right, although I like the defensive nature of Glaxo’s diverse portfolio.

In the meantime, I believe GlaxoSmithKline’s 5.5% dividend yield and long-term growth potential make the shares a strong buy.

Heading in the opposite direction?

While GlaxoSmithKline may have underperformed the market, National Grid hasn’t.

Over the last five years, shares in National Grid have risen by 69%, compared to just 3% for the FTSE 100. The two other large listed power utilities in the UK, SSE and Centrica, have also lagged National Grid. Centrica has fallen by nearly 30% over the same period, while SSE has gained just 17%.

National Grid also has a couple of other attractive features. The firm’s US utility business helps diversify the group’s operations and reduce its dependency on the UK market. Another attraction is that unlike electricity generators like SSE and Centrica, National Grid’s direct exposure to coal, oil and gas prices is very low.

I can’t see any reason why National Grid’s business can’t continue to perform strongly. My only reservation is that the shares are no longer obviously cheap. Dividend growth has now slowed to just 1% to 2% a year. And National Grid’s 4.3% yield is well below the 6% on offer from SSE.

However, analysts have a positive outlook for the next couple of years. Forecast earnings for 2015/16 have risen by 5.5% over the last year. There’s a real possibility that National Grid will continue to outperform its utility peers.

Roland Head owns shares of GlaxoSmithKline and SSE. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Friends and sisters exploring the outdoors together in Cornwall. They are standing with their arms around each other at the coast.
Investing Articles

£503 buys 14 shares in this FTSE 250 stock that returned 23.9% annually for the last 15 years

This FTSE 250 stock has averaged a huge return for 15 years. At today's price, £503 buys 14 shares. But…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

£1,000 buys 25 shares in this FTSE 100 stock that’s returned 29.2% annually for the last 10 years

This FTSE 100 mining stock has returned close to 30% a year for a decade. At 3,995p, £1,000 buys 25…

Read more »

Female student sitting at the steps and using laptop
Investing Articles

Down 47%, is this growth stock finally worth buying in May?

With a £288m order book and a hidden pipeline of defence and nuclear contracts, is this growth stock now too…

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

2 REITs yielding 7%+ to consider for passive income in 2026

A REIT backed by the NHS and another backed by Tesco and Sainsbury's with both yielding 7%+. Here's why I'm…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

Just 97 shares of this UK dividend stock generate £238 in passive income

A 5.7% yield, £238 in passive income from just 97 shares, and one of the most divisive dividend stocks on…

Read more »

ISA coins
Investing Articles

£10,000 in an ISA generates a second income of…

The London Stock Exchange is home to some of the world's most generous dividends. But how big a second income…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Expert recommendations: 2 top income stocks yielding 7%+!

With yields of 7.2% and 7.8% respectively, these two income stocks are catching the eyes of institutional analysts. Should investors…

Read more »

Illustration of flames over a black background
Investing Articles

3 top income-focused stocks to buy in May 2026, according to experts

Looking for a stock to buy for income in May 2026? Experts have flagged these three UK dividend shares as…

Read more »